**A focus on prostate cancer screening**

**Poster Session 21**

**Location:** Blue Area, Room 2 (Level 0)

**Chairs:**
- A.M. Mizokami, Kanazawa (JP)
- M. Roobol, Rotterdam (NL)
- P. Stattin, Uppsala (SE)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**266**

**Screening and prostate cancer mortality: Results of a unique cohort at 19 years of follow-up**

By: Osses D.¹, Remmers S.², Schröder F.², Van Der Kwast T.³, Roobol M.²

¹Erasmus University Medical Center, Dept. of Urology, Dept. Radiology and Nuclear Medicine, Rotterdam, Netherlands, The, ²Erasmus University Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, ³Erasmus University Medical Center, Dept. of Pathology, Rotterdam, Netherlands, The

---

**267**

**The German risk-adapted Prostate Cancer Screening Trial (PROBASE): First results after recruitment of 30.000 men**

By: Arsov C.¹, Becker N.², Herkommer K.³, Gschwend J.³, Imkamp F.⁴, Kuczyk M.⁴, Hadaschik B.⁵, Hohenfellner M.⁶, Siener R.⁷, Kristiansen G.⁸, Schimmöller L.⁹, Antoch G.⁹, Albers P.¹

¹University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²German Cancer Research Center, Dept. of Cancer Epidemiology, Heidelberg, Germany, ³Technical University of Munich, Dept. of Urology, Munich, Germany, ⁴Hanover Medical School, Dept. of Urology, Hanover, Germany, ⁵University of Duisburg-Essen, Dept. of Urology, Essen, Germany, ⁶University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ⁷University of Bonn, Dept. of Urology, Bonn, Germany, ⁸University of Bonn, Dept. of Pathology, Bonn, Germany, ⁹University of Düsseldorf, Dept. of Radiology, Düsseldorf, Germany

---

**268**

**Step-wise increase in high-risk pathological outcomes as a consequence of decreased screening: A population-based analysis**

By: Huynh L.¹, Ranasinghe O¹, Ahlering T¹

University of California, Irvine, Dept. of Urology, Orange, United States of America

---

**269**

**Unintended consequences of decreased PSA-based prostate cancer screening**

By: Ahlering T¹, Huynh L¹, Kaler K¹, Williams S², Osann K³, Joseph J⁴, Lee D¹
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>270</td>
<td>Blood glucose balance and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Prostate Cancer Screening</td>
<td>Murtola T., Sälli S., Talala K., Taari K., Tammela T., Auvinen A.</td>
<td>University of Tampere, Faculty of Medicine and Life Sciences, Tampere, Finland, Finnish Cancer Registry, Dept. of Statistics, Helsinki, Finland, University of Helsinki and Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, Tampere University Hospital, Dept. of Urology, Tampere, Finland, University of Tampere, Faculty of Social Sciences, Tampere, Finland</td>
</tr>
<tr>
<td>271</td>
<td>Development of prostate specific antigen (PSA) screening nomograms for 15-year prediction of prostate cancer diagnosis (PCDx), mortality (PCM), and all-cause mortality (ACM)</td>
<td>Carlsson S., Brooks M., Zajichek A., Chagin K., Hugosson J., Kattan M., Stephenson A.</td>
<td>Cleveland Clinic, Dept. of Urology, Cleveland, United States of America, Cleveland Clinic, Dept. of Quantitative Health Sciences, Cleveland, United States of America, Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden</td>
</tr>
<tr>
<td>272</td>
<td>The association between physician trust and prostate specific antigen screening: Implications for shared decision making</td>
<td>Klaassen Z., Wallis C., Goldberg H., Chandrasekar T., Fleshner N., Finelli A., Kulkarni G., Satkunasivam R.</td>
<td>University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, Houston Methodist Hospital, Dept. of Urology, Houston, United States of America</td>
</tr>
<tr>
<td>273</td>
<td>Decision aids for prostate cancer screening choice: A systematic review and meta-analysis</td>
<td>Riikonen J., Guyatt G., Kilpeläinen T., Craigie S., Agarwal A., Agoritsas T., Couban R., Dahm P., Järvinen P., Montori V., Power N., Richard P., Rutanen J., Santti H., Tailly T., Violette P., Zhou Q., Tikkinen K.</td>
<td>University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, Houston Methodist Hospital, Dept. of Urology, Houston, United States of America, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, University of Toronto, Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada</td>
</tr>
</tbody>
</table>
Incidence and survival trends of de-novo metastatic prostate cancer - a population-based analysis of two national cohorts from USA and Denmark

By: Helgstrand J.T. 1, Røder M. 1, Klemann N. 1, Toft B. 2, Lichtensztajn D. 3, Brooks J. 4, Brasso K. 1, Vainer B. 2, Iversen P. 1

1Copenhagen University Hospital, Dept. of Urology, Copenhagen, Denmark, 2Copenhagen University Hospital, Dept. of Pathology, Copenhagen, Denmark, 3Cancer Prevention Institute of California, Dept. of Urology, Fremont Ca, United States of America, 4Stanford University Hospital, Dept. of Urology, Stanford Ca, United States of America

Prostate cancer mortality in the five Nordic countries for the last 3 decades

By: Poulsen M.H. 1, Mortensen M. 1, Gerke O. 2, Lund L. 1

1Odense University Hospital, Dept. of Urology, Odense, Denmark, 2Odense University Hospital, Dept. of Nuclear Medicine, Odense, Denmark

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. A nationwide population-based study

By: Tomic K. 1, Ventimiglia E. 2, David R. 3, Lambe M. 4, Stattin P. 5

1Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, 2San Raffaele Hospital, University Vita-salute San Raffaele, Division of Experimental Oncology, Unit of Urology, Milan, Italy, 3Ryhop Hospital, Dept. of Urology, Jönköping, Sweden, 4Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 5Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden

Refer for prostate biopsy? A prediction tool combining risk of significant prostate cancer and life expectancy for UK primary care

By: Verbeek J. 1, Roobol M. 1, Parker C. 2, Kattan M. 3, Nieboer D. 4, Steyerberg E. 4

1Erasmus Medical Center, Dept. of Urology, Rotterdam, Netherlands, The, 2Clinical Oncology Academic Unit, Royal Marsden NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3Cleveland Clinic, Dept. of Quantitative Health Sciences, Cleveland, OH, United States of America, 4Erasmus Medical Center, Dept. of Public Health, Rotterdam, Netherlands, The
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Status</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>278</td>
<td><strong>Withdrawn</strong></td>
<td></td>
<td>To be confirmed</td>
</tr>
<tr>
<td>279</td>
<td><strong>Tumor associated neutrophils suppress CD8+ T cells responsiveness through galectin-9/Tim-3 to deteriorate survival in human renal cancer</strong></td>
<td></td>
<td>To be confirmed</td>
</tr>
</tbody>
</table>